COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings - Takeaways - MDSpire
Clinical Guidelines

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Share

  • 1

    Metastatic breast cancer patients had an 8-month survival advantage in community oncology practices.

  • 2

    Non-small cell lung cancer patients had a 2-month survival advantage.

  • 3

    The study involved nearly 98,000 patients.

  • 4

    Community oncology refers to independent physician-owned practices.

  • 5

    Research was conducted by Flatiron Health in collaboration with COA.

Original Source(s)

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

  • by The ASCO Post Staff

  • May 4, 2026

Related Content

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min
Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...

Early-Onset ICI-Related Myocarditis Linked to Increased Mortality

Early-onset of immune checkpoint inhibitor (ICI)-related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Assoc...